✦ LIBER ✦

8713 Addition of bevacizumab to the multi-modality standard of care in patients with newly diagnosed glioblastoma: a phase III trial

✍ Scribed by Chinot, O.; de La Motte Rouge, T.; Moore, N.; Zeaiter, A.

Book ID: 122373874
Publisher: Elsevier Science
Year: 2009
Tongue: English
Weight: 50 KB
Volume: 7
Category: Article
ISSN: 1359-6349
DOI: 10.1016/S1359-6349(09)71687-8

No coin nor oath required. For personal study only.

📜 SIMILAR VOLUMES

Addition of Bevacizumab to Standard Radi

Addition of Bevacizumab to Standard Radiation Therapy and Daily Temozolomide Is Associated With Minimal Toxicity in Newly Diagnosed Glioblastoma Multiforme

✍ James J. Vredenburgh; Annick Desjardins; John P. Kirkpatrick; David A. Reardon; 📂 Article 📅 2012 🏛 Elsevier Science 🌐 English ⚖ 668 KB

Integration of autologous dendritic cell

Integration of autologous dendritic cell-based immunotherapy in the standard of care treatment for patients with newly diagnosed glioblastoma: results of the HGG-2006 phase I/II trial

✍ Hilko Ardon, Stefaan W. Van Gool, Tina Verschuere, Wim Maes, Steffen Fieuws, Raf 📂 Article 📅 2012 🏛 Springer-Verlag 🌐 English ⚖ 353 KB

Phase II Trial of Hypofractionated Inten

Phase II Trial of Hypofractionated Intensity Modulated Radiotherapy to 60 Gy in 10 Fractions with Temozolomide Chemotherapy for Patients with Newly Diagnosed Glioblastoma Multiforme

✍ K. Reddy; D. Damek; L. Gaspar; D. Ney; B. Kavanagh; A. Waziri; K. Lillehei; K. S 📂 Article 📅 2011 🏛 Elsevier Science 🌐 English ⚖ 40 KB

Bortezomib Induction and Maintenance Tre

Bortezomib Induction and Maintenance Treatment in Patients With Newly Diagnosed Multiple Myeloma: Results of the Randomized Phase III HOVON-65/ GMMG-HD4 Trial

✍ Sonneveld, P.; Schmidt-Wolf, I. G. H.; van der Holt, B.; el Jarari, L.; Bertsch, 📂 Article 📅 2012 🏛 American Society of Clinical Oncology 🌐 English ⚖ 232 KB

Sequential Combination of Gemtuzumab Ozo

Sequential Combination of Gemtuzumab Ozogamicin and Standard Chemotherapy in Older Patients With Newly Diagnosed Acute Myeloid Leukemia: Results of a Randomized Phase III Trial by the EORTC and GIMEMA Consortium (AML-17)

✍ Amadori, S.; Suciu, S.; Stasi, R.; Salih, H. R.; Selleslag, D.; Muus, P.; De Fab 📂 Article 📅 2013 🏛 American Society of Clinical Oncology 🌐 English ⚖ 249 KB

25 FRAGMATIC. A randomised phase III cli

25 FRAGMATIC. A randomised phase III clinical trial investigating the effect of FRAGMin® added to standard therapy in patients with lung cancer

✍ Macbeth, F.; Noble, S.; Linnane, S.J. 📂 Article 📅 2007 🏛 Elsevier Science 🌐 English ⚖ 46 KB